English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Pro

Presents the zaia usage as premium feature

ZAIA

Presents AI Discovery search usage as a premium feature

AI Discovery

Presents AI Discovery explain and summary usage as a premium feature

Content Analysis

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Presents the pdf analysis as premium feature

PDF Analysis

1500 Top-up

3000 Top-up

Zendy Basic

2500 Top-up

Zendy Unlimited

Presents the access of premium content as premium feature

Premium Content

Anti-pl 55/140 autoantibody-positive dermatomyositis is a distinct subgroup with internal malignancies and characteristic clinical features, e.g. prominent cutaneous manifestation and lack of interstitial pneumonia ( 1 ). The target antigens ofp 155/140 have recently been identified as transcriptional intermediary factor ly (TIFly) and TIFla, respectively (2). It is thus speculated that TIFly is expressed in malignant tumour cells, leading to the development of anti-pl 55/140 autoantibody and the resultant occurrence of dermatomyositis. We report here the first case of anti-pl 55/140 antibody-positive dermatomyositis that shows the coexistence of a TIFly-overexpressing malignant neoplasm.

acta dermato venereologica

TIF1γ-overexpressing, Highly Progressive Endometrial Carcinoma in a Patient with Dermato-myositis Positive for Malignancy-associated Anti-p155/140 Autoantibody